Biomedical research produces a flood of information that no scientist can realistically absorb. At the University of Edinburgh, bioengineer Filippo Menolascina is using Co-Scientist to comb the literature for overlooked links and generate new hypotheses.

His team focused on a common liver disease called metabolic dysfunction‑associated steatohepatitis (MASH). Developing treatments is challenging because MASH involves intertwined biological processes, including liver inflammation and metabolism, meaning single‑target drugs fall short. That pushes researchers toward combination treatments, but the number of potential drug pairings is overwhelming.

Faced with that combinatorial explosion, Menolascina used Co‑Scientist to narrow the search.…